Although sleep apnea syndrome reportedly increases nocturnal blood glucose (BG) variability, few studies have assessed the effect of the lowest oxygen saturation (SpO2) during sleep on short-term BG levels. Thus, this prospective study of BG fluctuations while sleeping was conducted on subjects fitted with a continuous glucose monitoring (CGM) device and a WatchPAT®, allowing simple evaluation of sleep-disordered breathing. Ninety-two patients with type 2 diabetes were fitted with the two devices overnight in the hospital when the glycemia was stable (∼7-10 days) in order to avoid the effects of hyperglycemia. The subjects were aged at least 18 years.

Results: The subjects were categorized according to their lowest SpO2 by WatchPAT (SpO2 ≥90%, 85%≤ and <90%, or <85%). As SpO2 decreased, elevated body mass index (BMI) (20.3±3.3 vs. 25.3±3.9 vs. 28.7±5.8 kg/m2, mean±standard deviation (SD); p<0.001) and increased endogenous insulin secretion (1.3±0.7 vs. 2.2±1.1 vs. 2.5±1.3 ng/mL; p=0.002) were observed. Using BG level at the time of the lowest SpO2 as baseline, comparison of the differences in BG values every 30 minutes for 3 hours showed significantly worsened BG levels for SpO2 <90% (30 min-baseline 4.4±3.2 vs. 180 min-baseline 18.7±22.4 mg/dL; p<0.001). In addition, in the 30 minutes after the lowest SpO2, the BG level was elevated in the SpO2 <85% group compared to those in the other groups (SpO2 ≤90% 4.1±3.2 vs. 85%≤ SpO2 <90% 4.4±3.2 vs. SpO2 <85% 7.8±6.9 mg/dL; p=0.03). In contrast, no significant differences were noted in mean BG, mean amplitude of glycemic excursions (MAGE), SD, or coefficient of variation (CV) among the three groups from 00:00 to 06:00.

Conclusions: Even without differences in nocturnal fluctuations of BG levels, because of treatment, hypoxemia during sleep causes short-term worsening of glycemia. Moreover, the greater the degree of hypoxemia, the earlier the worsening is likely.

Disclosure

M. Shinoda: None. T. Yamakawa: None. R. Sakamoto: None. J. Suzuki: None. K. Takahashi: None. Y. Terauchi: Research Support; Self; MSD K.K.. Speaker's Bureau; Self; MSD K.K.. Advisory Panel; Self; MSD K.K.. Research Support; Self; Ono Pharmaceutical Co., Ltd.. Speaker's Bureau; Self; Ono Pharmaceutical Co., Ltd.. Research Support; Self; Novartis Pharma K.K., Boehringer Ingelheim GmbH. Speaker's Bureau; Self; Boehringer Ingelheim GmbH. Advisory Panel; Self; Boehringer Ingelheim GmbH. Research Support; Self; Mitsubishi Tanabe Pharma Corporation. Speaker's Bureau; Self; Mitsubishi Tanabe Pharma Corporation. Advisory Panel; Self; Mitsubishi Tanabe Pharma Corporation. Research Support; Self; Daiichi Sankyo Company, Limited. Speaker's Bureau; Self; Daiichi Sankyo Company, Limited. Advisory Panel; Self; Daiichi Sankyo Company, Limited. Research Support; Self; Sanwa Kagaku Kenkyusho Co., Ltd.. Speaker's Bureau; Self; Sanwa Kagaku Kenkyusho Co., Ltd.. Research Support; Self; Novo Nordisk Inc.. Speaker's Bureau; Self; Novo Nordisk Inc.. Advisory Panel; Self; Novo Nordisk Inc.. Research Support; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Advisory Panel; Self; Eli Lilly and Company. Research Support; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Advisory Panel; Self; Sanofi. Research Support; Self; Sumitomo Dainippon Pharma Co., Ltd.. Speaker's Bureau; Self; Sumitomo Dainippon Pharma Co., Ltd.. Research Support; Self; Shionogi & Co., Ltd.. Speaker's Bureau; Self; Shionogi & Co., Ltd., Bayer Yakuhin, Ltd., Astellas Pharma US, Inc., AstraZeneca. Advisory Panel; Self; AstraZeneca, Teijin Pharma Limited.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.